Prorenin receptor blockers: Effects on cardiovascular complications of diabetes and hypertension

Expert Opinion on Investigational Drugs

Volumn 15, Issue 10, 2006, Pages 1137-1139

  Ichihara, Atsuhiro ^a   Kaneshiro, Yuki ^a   Suzuki, Fumiaki ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b GIFU UNIVERSITY   (Japan)

Author keywords

Angiotensin; Cardiac fibrosis; Mitogen activated protein kinases; Nephropathy; Retinopathy

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN II; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PRORENIN; PRORENIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; EDITORIAL; ENZYME ACTIVE SITE; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY FAILURE; NONHUMAN; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; RECEPTOR BINDING; RECEPTOR BLOCKING; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DRUGS, INVESTIGATIONAL; HUMANS; HYPERTENSION; RECEPTORS, CELL SURFACE; RENIN;

EID: 33750274126     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.10.1137     Document Type: Editorial

References (20)

1. LEWIS EJ, HUNSICKER LG, CLARKE WR et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. (2001) 345:851-860.
2. BRENNER BM, COOPER ME, DE ZEEUW D et al.: Effects of losartan on renal and cardiovascular outocomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. (2001) 345:861-869.
3. DE CAVANAGH EMV, INSERRA F, TOBLLI J, STELLA I, FRAGA CG, FERDER L: Enalapril attenuates oxidative stress in diabetic rats. Hypertension (2001) 38:1130-1136.
4. ONOZATO ML, TOJO A, GOTO A, FUJITA T, WILCOX CS: Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int. (2002) 61:186-194.
5. ICHIHARA A, HAYASHI M, KANESHIRO Y et al.: Inhibition of diabetic nephropathy by a decoy peptide corresponding to the 'handle' region for non-proteolytic activation of prorenin. J. Clin. Invest. (2004) 114:1128-1135.
6. NGUYEN G, DELARUE F, BURCKLE C, BOUZHIR L, GILLER T, SRAER J-D: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. (2002) 109:1417-1427.
7. 1, and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. (2006) 69(1):105-113.
8. ICHIHARA A, SUZUKI F, NAKAGAWA T et al: Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor deficient mice. J. Am. Soc. Nephrol. (2006) 17:1950-1961.
9. KHAN KN, STANFIELD KM, HARRIS RK, BARON DA: Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Renal Fail. (2001) 23(3-4):321-330.
10. KOMERS R, LINDSLEY JN, OYAMA TT et al.: Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J. Clin. Invest. (2001) 107(7):889-898.
11. KANESHIRO Y, ICHIHARA A, TAKEMITSU T et al.: Increased expression of cyclooxygenase-2 in renal cortex of human-prorenin-receptor-gene transgenic rats. Kidney Int. (2006) 70:641-646.
12. SATOFUKA S, ICHIHARA A, NAGAI N et al.: Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin. Invest. Ophthalmol. Vis. Sci. (2006) 47(6):2686-2692.
13. OBATA J, NAKAMURA T, TAKANO H et al.: Increased gene expression of components of the renin-angiotensin system in glomeruli of genetically hypertensive rats. J. Hypertens. (2000) 18(9):1247-1255.
14. ICHIHARA A, KANESHIRO Y, TAKEMITSU T et al.: Non-proteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension (2006) 47:894-900.
15. VENIANT M, MENARD J, BRUNEVAL P, MORLEY S, GONZALES MF, MULLINS J: Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J. Clin. Invest. (1996) 98:1966-1970.
16. ICHIHARA A, KANESHIRO Y, TAKEMITSU T et al.: Contribution of non-proteolytically activated prorenin in glomeruli to hypertensive renal damage. J. Am. Soc. Nephrol. (2006) 17(9):2495-2503.
17. SUZUKI F, HAYAKAWA M, NAKAGAWA T et al.: Human prorenin has 'gate and handle' regions for its non-proteolytic activation. J. Biol. Chem. (2003) 278:22217-22222
18. DANSER AH, DEINUM J: Renin, prorenin and the putative (pro)renin receptor. Hypertension (2005) 46(5):1069-1076.
19. NGUYEN G: Renin/prorenin receptors. Kidney Int. (2006) 69(9):1503-1506
20. DANSER AH: Prorenin: back into the arena. Hypertension (2006) 47(5):824-826.